CEL-SCI's L.E.A.P.S.™ H1N1 Flu Development Seen as Credibility Booster
BioMedReports.com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, reports that one of several expected key news developments has been announced by CEL-SCI Corporation (NYSE Amex: CVM), today.
An Institutional Review Board of The Johns Hopkins University School of Medicine (Johns Hopkins) has given clearance for the Company's first clinical study involving the much talked about L.E.A.P.S.™ H1N1 investigational therapy.
The initiation of CEL-SCI's rapidly-accelerated LEAPS-H1N1 clinical development program builds on CEL-SCI's pioneering work with its L.E.A.P.S.™ technology, whose reach goes beyond the H1N1 space, and whose responses can be designed to be directed at a great number of human diseases.
Investors, who have sent the stock price up on the news, apparently also view the news as a much needed credibility boost in light of recent attacks by a single columnist against the company. Despite those published attacks, shares of the company have risen dramatically in the past few months and many expect that trend to continue as the company moves forward on several fronts, including a pending, and long anticipated launch of Phase III trials for Multikine®, CEL-SCI's flagship cancer immunotherapeutic agent, which is being developed as a first-line standard of care cancer treatment.
The complete report is available now at BioMedReports.com:
Biotech investors interested in accessing the news portal's complete database of clinical trials and upcoming FDA decisions can access that information here:
BioMedReports.com is a news portal covering the biomedical news and financial sector. (b)BioMedReports is not paid, compensated or in any way incentivized to report news and developments about publicly traded companies.(/b)
News 
Market Data 
Discover 
AI
